<DOC>
	<DOCNO>NCT00926640</DOCNO>
	<brief_summary>BACKGROUND : - The histone deacetylase ( HDAC ) inhibitor novel class anticancer agent . These agent lead increase acetylation histone non-histone protein , lead rapid cell death many tumor model . It think cell death observed class agent may mediate , part , selective acetylation histone proteins result increase expression specific gene . - For solid tumor general , cell death preclinical model translate activity patient . For reason , study increasingly combine chemotherapy HDAC inhibitor achieve additive potentially synergistic effect cancer cell . - This protocol study continuous infusion HDAC inhibitor belinostat combination cisplatin etoposide patient advanced cancer . OBJECTIVES : - To determine safe tolerable phase 2 dose combination belinostat cisplatin etoposide . - Evaluate molecular marker HDAC inhibition . ELIGIBILITY : - The protocol open patient recurrent advanced cancer ( small-cell lung cancer advance cancer ) standard therapy offer curative potential . - Age great equal 18 year - ECOG Performance Status 0-2 DESIGN : - The study begin belinostat 400 mg/m ( 2 ) /24h administer continuous IV infusion day 1 2 , cisplatin 80 mg/m ( 2 ) IV day 2 , etoposide 100 mg/m ( 2 ) IV daily time 3 day 2 - 4 . Dose escalation belinostat follow accord traditional 3 patient cohort . - Treatment schedule dose escalation schema .</brief_summary>
	<brief_title>A Phase I Study Belinostat Combination With Cisplatin Etoposide Adults With Small Cell Lung Carcinoma Other Advanced Cancers</brief_title>
	<detailed_description>BACKGROUND : - The histone deacetylase ( HDAC ) inhibitor novel class anticancer agent . These agent lead increase acetylation histone non-histone protein , lead rapid cell death many tumor model . It think cell death observed class agent may mediate , part , selective acetylation histone proteins result increase expression specific gene . - For solid tumor general , cell death preclinical model translate activity patient . For reason , study increasingly combine chemotherapy HDAC inhibitor achieve additive potentially synergistic effect cancer cell . - This protocol study continuous infusion HDAC inhibitor belinostat combination cisplatin etoposide patient advanced cancer . OBJECTIVES : - To determine safe tolerable phase 2 dose combination belinostat cisplatin etoposide . - Evaluate molecular marker HDAC inhibition . - To explore result administer dose belinostat base patient ' UGT1A1 *28 *60 genotype , characteristic may associate toxicity . ELIGIBILITY : - The protocol open patient recurrent advanced cancer ( small-cell lung cancer advance cancer ) standard therapy offer curative potential . - Age great equal 18 year - ECOG Performance Status 0-2 DESIGN : - The study begin belinostat 400 mg/m ( 2 ) /24h administer continuous IV infusion day 1 2 , cisplatin 60 mg/m ( 2 ) IV day 2 , etoposide 80 mg/ ( 2 ) IV daily time 3 day 2 - 4 . Dose escalation belinostat follow accord traditional 3 patient cohort . - With Amendment M , dose base UGT1A1 status , either 400 mg/m ( 2 ) 600 mg/m ( 2 )</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Carcinoma , Neuroendocrine</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Belinostat</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Histone Deacetylase Inhibitors</mesh_term>
	<criteria>INCLUSION CRITERIA : 1 . Patients must histologic cytologic confirmation cancer know standard therapy capable extend life expectancy . 2 . Patients must great equal 4 week cytotoxic chemotherapy , except great equal 6 week mitomycin C nitrosoureas , great equal 8 week prior UCN01 ; great equal 4 week monoclonal antibody therapy ( cetuximab , bevacizumab ) ; great equal 4 week prior experimental therapy ; great equal 2 week radiation hormonal therapy ; great equal 2 week sorafenib , sunitinib temsirolimus treatment . Patients prostate cancer may continue ongoing LhRH agonist therapy . Patients bone metastasis hypercalcemia begin intravenous bisphosphonate treatment prior study entry may continue treatment study . 3 . ECOG performance status 02 . 4 . Life expectancy 3 month great . 5 . Patients must acceptable organ marrow function define : absolute neutrophil count great equal 1,500/ mm ( 3 ) platelet great equal 100,000/ mm ( 3 ) total bilirubin less equal 1.2 mg/dL ( except patient Gilbert 's Syndrome ) AST ( SGOT ) ALT ( SGPT ) less equal 2.5 time institutional upper limit normal creatinine less equal 1.5 time institutional upper limit normal OR creatinine clearance &gt; 50 mL/min/1.73 ( 2 ) patient creatinine level institutional normal . 6 . Women childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry , study , 3 month study participation . Should woman become pregnant suspect pregnant participating study , inform treat physician immediately . 7 . Age great equal 18 year . 8 . Ability understand willingness sign write informed consent document . 9 . Willing comply study procedure followup . EXCLUSION CRITERIA : 1 . Patients recover ( CTCAE less equal grade 1 ) adverse event due prior treatment , except alopecia base stable grade 2 tinnitus ( interfere ADL ) stable grade 2 sensory neuropathy without pain motor component , interfere ADL s. 2 . Patients may receive 2 prior cytotoxic regimen . 3 . Patients may receive investigational agent therapeutic anticancer intent . 4 . Patients may take another histone deacetylase inhibitor ( i.e . valproic acid , vorinostat ) least 2 week prior enrollment . 5 . Patients history CNS metastasis may enrol study , unless control achieve either radiation surgical resection least 3 month prior enrollment study . 6 . Patients radiation pelvis bone marrowbearing site consider case case basis may exclude bone marrow reserve consider adequate ( &gt; 25 % bone marrow ) . 7 . Uncontrolled medical illness include , limited ongoing active infection , chronic acute hepatitis , renal failure , symptomatic congestive heart failure , myocardial infarction unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . 8 . HIVpositive patient . 9 . Patients acute chronic hepatitis . 10 . Pregnant patient may receive experimental therapy . 11 . Significant cardiovascular disease , myocardial infarction within past 6 month , unstable angina , unstable arrhythmia need antiarrhythmic therapy ( use medication control heart rate patient atrial fibrillation allow , stable medication least last month prior randomization medication list cause Torsade de Points ) , evidence acute ischemia ECG . 12 . Baseline prolongation QT/QTc interval , i.e. , define average QTc interval &gt; 450 msec ; Long QT Syndrome ; require use concomitant medication may cause Torsade de Pointes .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>September 26, 2016</verification_date>
	<keyword>Solid Tumors</keyword>
	<keyword>Histone deacetylase inhibitor</keyword>
	<keyword>EP &amp; amp ; Belinostat</keyword>
	<keyword>Phase I</keyword>
	<keyword>SCLC</keyword>
	<keyword>Small Cell Lung Cancer</keyword>
</DOC>